Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease

Biochemical Pharmacology

Volumn 86, Issue 1, 2013, Pages 37-42

  Popp, Julius ^a,b   Meichsner, Sabrina ^c   Kölsch, Heike ^b   Lewczuk, Piotr ^d   Maier, Wolfgang ^b,e   Kornhuber, Johannes ^d   Jessen, Frank ^b,e   Lütjohann, Dieter ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

24S hydroxycholesterol; 27 hydroxycholesterol; Amyloid beta; Cerebrospinal fluid; Cholesterol; Cholesterol precursors; Tau

Indexed keywords

24 HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN[1-42]; CHOLESTEROL; DESMOSTEROL; LANOSTEROL; LATHOSTEROL; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID; BIOLOGICAL MARKER;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; NEUROPATHOLOGY; PRECURSOR; PRIORITY JOURNAL; BLOOD; BRAIN; CASE CONTROL STUDY; METABOLISM;

AGED; ALZHEIMER DISEASE; AMYLOID; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; HUMANS; MALE; TAU PROTEINS;

EID: 84884339335     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.12.007     Document Type: Article

References (51)

1. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimer's Dis 2009;18:413-7.
2. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009;10:333-44.
3. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 2009;65:650-7.
4. Popp J, Lewczuk P, Frommann I, Kolsch H, Kornhuber J, Maier W, et al. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEepsilon4 genotype. J Alzheimer's Dis 2010;22:459-68.
5. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PloS ONE 2010;5:e13950.
6. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-4. (Pubitemid 28249035)
7. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-61. (Pubitemid 32435732)
8. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003;160:113-23. (Pubitemid 36091721)
9. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, et al. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis 2008;29:422-37.
10. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996;271:4436-40.
11. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-31.
12. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 2005;7:1118-23.
13. Canepa E, Borghi R, Vina J, Traverso N, Gambini J, Domenicotti C, et al. Cholesterol and amyloid-beta: evidence for a cross-talk between astrocytes and neuronal cells. J Alzheimer's Dis 2011;25:645-53.
14. Famer D, Meaney S, Mousavi M, Nordberg A, Bjorkhem I, Crisby M. Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem Biophys Res Commun 2007;359:46-50. (Pubitemid 46844819)
15. Marwarha G, Dasari B, Prasanthi JR, Schommer J, Ghribi O. Leptin is involved in accumulation of amyloid-beta and tau phosphorylation induced by 27-hydroxycholesterol in organotypic slices from adult rabbit hippocampus. J Alzheimer's Dis 2010;19(3):1007-19.
16. Dasari B, Prasanthi JR, Marwarha G, Singh BB, Ghribi O. The oxysterol 27- hydroxycholesterol increases beta-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol 2010;10:22.
17. Sharma S, Prasanthi RPJ, Schommer E, Feist G, Ghribi O. Hypercholesterolemiainduced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol Dis 2008;32:426-32.
18. Prasanthi JR, Huls A, Thomasson S, Thompson A, Schommer E, Ghribi O. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol Neurodegen 2009;4:1.
19. Prasanthi JR, Larson T, Schommer J, Ghribi O. Silencing GADD153/CHOP gene expression protects against Alzheimer's disease-like pathology induced by 27- hydroxycholesterol in rabbit hippocampus. PloS ONE 2011;6:e26420.
20. Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck GW. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver recepreceptor agonists increases secreted Abeta levels. J Biol Chem 2002;277: 48508-13. (Pubitemid 35470811)
21. Brown 3rd J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 2004;279:34674-81. (Pubitemid 39318097)
22. Ferrera P, Mercado-Gomez O, Silva-Aguilar M, Valverde M, Arias C. Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochem Res 2008;33:1509-17.
23. Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS, et al. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem 2008;106:475-85. (Pubitemid 351840227)
24. Gamba P, Leonarduzzi G, Tamagno E, Guglielmotto M, Testa G, Sottero B, et al. Interaction between 24-hydroxycholesterol, oxidative stress, and amyloidbeta in amplifying neuronal damage in Alzheimer's disease: three partners in crime. Aging Cell 2011;10:403-17.
25. Kolsch H, Lutjohann D, Tulke A, Bjorkhem I, Rao ML. The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Brain Res 1999;818:171-5. (Pubitemid 29227299)
26. Kolsch H, Ludwig M, Lutjohann D, Rao ML. Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J Neural Transm 2001;108: 475-88. (Pubitemid 32703896)
27. Ong WY, Kim JH, He X, Chen P, Farooqui AA, Jenner AM. Changes in brain cholesterol metabolome after excitotoxicity. Mol Neurobiol 2010;41:299-313.
28. Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 2010;45:408-17.
29. Glockner F, Meske V, Lutjohann D, Ohm TG. Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. J Neuropathol Exp Neurol 2011;70:292-301.
30. Rahman A, Akterin S, Flores-Morales A, Crisby M, Kivipelto M, Schultzberg M, et al. High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 2005;579:6411-6. (Pubitemid 41612160)
31. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004;101:2070-5. (Pubitemid 38229016)
32. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001;57:1447-52. (Pubitemid 32995727)
33. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003;61:199-205. (Pubitemid 36875301)
34. Matsuzaki T, Sasaki K, Hata J, Hirakawa Y, Fujimi K, Ninomiya T, et al. Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama study. Neurology 2011;77:1068-75.
35. Popp J, Lewczuk P, Kolsch H, Meichsner S, Maier W, Kornhuber J, et al. Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. J Neurochem 2012;123(2):310-6.
36. Leoni V, Shafaati M, Salomon A, Kivipelto M, Bjorkhem I, Wahlund LO. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment. Neurosci Lett 2006;397:83-7. (Pubitemid 43340464)
37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
38. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
39. Kolsch H, Heun R, Jessen F, Popp J, Hentschel F, Maier W, et al. Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim Biophys Acta 2010;1801:945-50.
40. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8. (Pubitemid 20107994)
41. Usui K, Hulleman JD, Paulsson JF, Siegel SJ, Powers ET, Kelly JW. Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc Natl Acad Sci USA 2009;106:18563-68.
42. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2004;24:3801-9. (Pubitemid 38509410)
43. Hernandez P, Lee G, Sjoberg M, Maccioni RB. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts. J Alzheimer's Dis 2009;16:149-56.
44. Nicholson AM, Ferreira A. Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity. J Neurosci 2009;29:4640-51.
45. Yamanaka K, Saito Y, Yamamori T, Urano Y, Noguchi N. 24(S)- hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis. J Biol Chem 2011;286:24666-73.
46. Bjorkhem I, Cedazo-Minguez A, Leoni V, Meaney S. Oxysterols and neurodegenerative diseases. Mol Aspects Med 2009;30:171-9.
47. Leoni V, Caccia C. Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 2011;164:515-24.
48. Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech 2012;5:746-55.
49. Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease. Nat Rev Neurol 2011;7:561-72.
50. Vanmierlo T, Popp J, Kolsch H, Friedrichs S, Jessen F, Stoffel-Wagner B, et al. The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease. Acta Psychiatr Scand 2011;124:184-92.
51. Lutjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann K, et al. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res 2002;43:1078-85. (Pubitemid 34760879)